<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01228266</url>
  </required_header>
  <id_info>
    <org_study_id>CMM-EM</org_study_id>
    <nct_id>NCT01228266</nct_id>
  </id_info>
  <brief_title>Mesenchymal Stem Cell Transplantation in MS</brief_title>
  <acronym>CMM-EM</acronym>
  <official_title>Autologous Mesenchymal Stem Cell Transplantation in Multiple Sclerosis: a Randomized, Double-blind, Crossover With Placebo Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert Saiz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Salud Carlos III</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a randomized Phase II study, masked and crossed-over with placebo to evaluate
      the safety and tolerability of autologous mesenchymal stem cell transplantation in patients
      with active multiple sclerosis
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Ended the recruitment in June 2012 for low enrollement accrual
  </why_stopped>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety as number of severe events along 1 year, and efficacy in terms of cumulative number of gadolinium-enhancing lesions in MRI at 6 months and at the end of the study</measure>
    <time_frame>12 months</time_frame>
    <description>The coprimary endpoints were safety and efficacy in terms of cumulative number of gadolinium-enhancing lesions in MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate effects on MS disease activity measured by: clinical variables, MRI, OCT, immunological analysis and quality of life scales</measure>
    <time_frame>12 months</time_frame>
    <description>clinical outcomes (number of relapses and change in the EDSS); MRI-based measures and OCT. Immunological evaluation as exploratory analysis</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>autologous mesenchymal stem cell</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single infusion of up to 2 million cells per Kg of autologous mesenchymal stem cells vs suspension media. The treatment will be reversed at 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>autologous mesenchymal stem cells</intervention_name>
    <description>A randomized double-blind, crossover study comparing treatment with autologous MSC vs. suspension media on patients with active MS</description>
    <arm_group_label>autologous mesenchymal stem cell</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Inflammatory forms of MS

               1. Relapsing-remitting MS (RRMS) patients

               2. Secondary progressive MS (SPMS) patients with continued relapses

               3. Primary progressive MS (PPMS) patients with enhancing MRI lesions and positive
                  CSF (oligoclonal banding)

          2. Age 18-50 years

          3. Disease duration &gt;= 2 and &gt;= 10 years

          4. EDSS 3.0 - 6.5

          5. Progression, continued relapses or worsening MRI after at least a year of attempted
             therapy evidenced by:

               1. Increase of &gt;= 1 EDSS point (if baseline EDSS &lt;= 5.0) or 0.5 EDSS points (if
                  baseline EDSS &gt;= 5.5), or quantifiable, objective evidence of equivalent
                  progression

               2. &gt;= 1 moderate-severe relapses in past 18 months

               3. &gt;= 1 Gadolinium enhancing lesions (double or triple dose Gadolinium)

               4. &gt;= 1 new T2 lesion

               5. For PPMS only, &gt;= 1 Gadolinium enhancing lesions

          6. Has given informed consent to participate in the study.

        Exclusion Criteria:

          1. SPMS without ongoing relapses

          2. PPMS without positive CSF or Gadolinium enhancing lesions

          3. &lt;= 3 months since treatment with any immunosuppressive therapy

          4. &lt;=1 month since last treatment with interferon-B or glatiramer acetate

          5. Corticosteroid treatment &lt;= 30 days

          6. Relapse &lt;= 60 days

          7. History of cancer or clinical or laboratory results indicative of severe systemic
             diseases, including infection for HIV, Hepatitis B or C

          8. Any metallic or electronic device that precludes from undergoing MRI

          9. Pregnancy or lactation

         10. Current treatment with an investigational therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert Saiz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Neurology Service, Hospital Clinic de barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2010</study_first_submitted>
  <study_first_submitted_qc>October 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2010</study_first_posted>
  <last_update_submitted>February 12, 2014</last_update_submitted>
  <last_update_submitted_qc>February 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinic of Barcelona</investigator_affiliation>
    <investigator_full_name>Albert Saiz</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

